Abstract. Arsenic trioxide has been used as a therapeutic agent for acute promyelocytic leukemia and recently for some solid tumors. Although arsenic trioxide has been shown to significantly inhibit the growth of solid tumor cells in vitro, clinical trials indicate that arsenic trioxide alone is pool active against non-hematologic malignant diseases. To understand the mechanisms of arsenic resistance in solid tumor cells, we established two arsenic-resistant solid tumor cell lines, HepG2/AS and SGC7901/AS, isolated from human liver cancer cell line HepG2 and human gastric cancer cell line SGC7901, respectively, by a series of stepwise selections via treatment with increasing concentrations of arsenic trioxide. Three ABC transporter proteins, ABCB1, ABCC1 and ABCC2, were expressed increasingly and differently in two arsenic-resistant cell lines. Further, tumor suppressor p53 was overexpressed in two arsenic-resistant cell lines, but the levels of p53 mediators MDM2 and gankyrin, which regulate the ubiquitination of p53, increased simultaneously. In addition, an increase in the phosphorylation of Rb at Ser795 in the two cell lines might also result from the presence of MDM2 and gankyrin, which suggest that the inactivation of p53 and Rb contribute to drug resistance. These two arsenic-resistant solid tumor cell lines, HepG2/AS and SGC7901/AS, may be useful for studying the mechanism of arsenic resistance in solid tumors and may provide a way to overcome it.
Introduction
Arsenic trioxide (As 2 O 3 ), a traditional Chinese medicine, has been used therapeutically for many years. It is widely used as an effective anti-cancer drug for acute promyelocytic leukemia (APL). Arsenic trioxide degrades the PML-RAR· fusion protein in APL cases characterized by chromosomal translocation t (15;17) and rearrangement of the promyelocytic leukemia (PML) gene and retinoic acid receptor (RAR·) gene and induces differentiation in lower concentrations (1, 2) . Unlike all-trans retinoic acid (ATRA), arsenic trioxide affects multiple intracellular signaling pathways and induces apoptosis of APL cells, with a higher concentration independent of the presence of the PML-RAR· fusion protein. Similarly, increasing evidence has shown that this inorganic arsenic compound can effectively inhibit the growth of solid tumors in the digestive tract by inducing apoptosis in vitro and in vivo, especially liver cancer, because most inorganic arsenicals are biotransferred in the liver (3, 4) .
Although hepatocellular carcinoma (HCC) is common, only rarely is it treatable by surgery. Systemic chemotherapy is difficult for patients with HCC to tolerate because hepatic function is often impaired by the invasion of malignant cells, by cirrhosis and by pool homeostasis. The lack of any clinically useful drug therapy for patients with advanced HCC poses difficulties also for physicians. Years before the noticeable anti-cancer activity of arsenic trioxide attracted the attention of oncologists, the effective therapeutic results in vitro and in vivo were surprising. However, recently a phase II trial evaluating the efficacy and toxicity of arsenic trioxide in patients with HCC showed that single-agent arsenic trioxide is pool active against advanced HCC (5) . Although several likely factors could explain the inefficacy of arsenic trioxide against advanced HCC, the appearance of drug resistance might be an important possibility.
Drugs fail to kill cancer cells for several reasons. Increasing efflux of anti-cancer drugs is most commonly encountered in laboratories and clinical medication mediated by membrane transporters. The ABC (ATP-binding cassette) transporter family is well known in this area, especially such members as ABCB1 [P-gp, P-glycoprotein, MDR1 (multidrug-resistance gene 1), ABCC1 (multidrug-resistant protein 1, MRP1)], ABCC2 (MRP2) and ABCG2 [breast cancer resistance protein (BCRP)] (6,7). The MRPs have been functionally characterized as the property of ATP-dependent export pumps for conjugates with glutathione (GSH), glucuronate, or sulfate (8) . With respect to arsenic compounds, GST (glutathione S-transferase) has been reported to conjugate glutathione to arsenicals and several GST isoforms and genetic polymorphisms might influence arsenic metabolism and susceptibility (9) . It should be pointed out that the arsenic-GSH conjugates are the substrates of some ABC transporter proteins, which efflux them outside mammalian cells (10) . In arsenic trioxide-resistant human leukemia cell line K562/AS-3, the main mechanism of tolerance seems to be drug efflux by MRP1 (11) . Chronic exposure to low-concentration arsenic trioxide or methylated arsenicals can increase the expression of P-gp, MRP1 and MRP2 at both the protein and mRNA level (12, 13) . However, there is no established arsenic-resistant human solid tumor cell line. Therefore, which of the ABC members contribute to arsenic resistance by actively pumping arsenic compounds outside solid tumors derived from the human digestive tract is still uncertain.
It is known that arsenic trioxide induces DNA damage and p53 accumulation and that arsenic trioxide-induced apoptosis is required for p53 (14, 15) . Reducing the expression or inhibiting the function of p53 may abrogate the apoptosis of tumor cells induced by arsenic trioxide. Several signaling pathways are involved in the regulation of p53; of these, ubiquitylation is the most common way for the degradation of p53 through the binding of MDM2 to p53 (16) . Previously, studies further verify that gankyrin promotes both mono-and poly-ubiquitylation of p53 by MDM2 in a p300-independent manner (17) . Direct interaction between gankyrin and MDM2 is necessary to enhance p53 ubiquitylation and gankyrin facilitates the binding of MDM2 to p53 in vivo and in vitro. This suggests that gankyrin could be a key point in the regulation of p53 and may contribute to the establishment of resistance to arsenic trioxide in tumor cells. Thus, we established two arsenic-resistant solid tumor cell lines, HepG2/AS and SGC7901/AS to investigate the reasons of resistance. Our results indicate that HepG2/AS seems to efflux arsenic compounds mainly by ABCB1, ABCC1, and ABCC2, whereas SGC7901/AS seems to efflux arsenic compounds mainly by ABCB1. Inactivation of ABCB1 by higher concentration of verapamil can restore the sensitivity of arsenic trioxide in HepG2/AS and SGC7901/AS. Increasing the levels of gankyrin and MDM2 may enhance the degradation of p53 and the phosphorylation of Rb, resulting in abrogation of apoptosis. A better understanding of arsenic resistance in solid tumor cells may provide novel targets for treating arsenic-resistant tumors and promote screening of suitable patients.
Materials and methods
Reagents. As 2 O 3 (Sigma, St. Louis, MO, USA) was dissolved in phosphate-buffered saline (PBS) at 200 μM as a stock solution, which was stored at 4˚C. For in vitro use, the stock solution was diluted to the appropriate concentration in growth medium. Fluorouracil (5-FU; Sigma) was dissolved in medium at 100 μg/l as a working solution, which was stored at 4˚C. Verapamil (Sigma) was dissolved in PBS at 1 mM as a stock solution, which was stored at 4˚C. Cell counting kit-8, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-8) was purchased from Beyotime Institute of Biotechnology (Shanghai, China). Gibco cell culture medium RPMI-1640 and fetal bovine serum were purchased from Invitrogen (Shanghai).
Cell culture. HepG2/AS and SGC7901/AS were isolated from the human liver cancer cell line, HepG2, and the human gastric cancer cell line, SGC7901, by a series of stepwise selections via treatment with increasing concentrations of arsenic trioxide. HepG2, HepG2/AS, SGC7901 and SGC7901/AS were cultured and passaged in RPMI-1640 supplemented with 10% fetal bovine serum in a 5% CO 2 incubator at 37˚C. HepG2/AS and SGC7901/AS were maintained in medium containing 2 μM As 2 O 3 .
Cytotoxicity. Cytotoxicity assays using WST-8, modified from the MTT assay, were performed. Briefly, 1x10 4 cells were plated per well with 100 μl of medium in 96-well microtiter plates. Cells were grown for 24 h, after which arsenic trioxide was added; the final concentration of the medium was 4 μM As 2 O 3 . After an additional 12, 24, 36 and 48 h of incubation, the medium was aspirated and the WST-8 solution was added. After incubation at 37˚C for 1.5 h, the optical density of each well was determined in a microplate reader by an absorbance spectrophotometer at a wavelength of 450 nm. Cell viability was measured and was expressed as a percentage of absorbance in the vehicle-treated control wells.
Western blot analysis. Protein extracts from total cells were harvested in radioimmunoprecipitation assay buffer [0.15 M NaCl/0.05 mM Tris-HCl; pH 7.2/1% NP-40/1% sodium deoxycholate/0.1% sodium dodecyl sulfate (SDS)] with 1 mM phenylmethyl sulfonylfluoride and then subjected to 10,000 x g centrifugation at 4˚C for 10 min. Protein levels were quantified using a bicinchoninic acid protein assay (Beyotime Biotechnology). A total of 40 to 50 μg of total protein was separated by denaturing electrophoresis. The following antibodies were used for immunoblotting: mouse monoclonal anti-ß-actin antibody (C4), mouse monoclonal anti-MDR1 antibody (D-11), mouse monoclonal anti-MRP1 antibody (QCRL-1), mouse monoclonal anti-MRP2 antibody (6D564), rabbit polyclonal anti-gankyrin antibody (H-231), mouse monoclonal anti-p53 antibody (DO-1), mouse monoclonal anti-MDM2 antibody (SMP14), rabbit polyclonal anti-Rb antibody (C-15), and goat polyclonal anti-p-Rb (Ser795) antibody (sc-7986), all purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). After SDS-PAGE (polyacrylamide gel electrophoresis) proteins were transferred to PVDF (polyvinylidene fluoride) sheets. After blocking with TTBS (50 mM Tris-HCl; pH 7.4; 0.5 M NaCl; 0.05% Tween-20) containing 5% (weight per volume) skim milk, the sheets were incubated with primary antibodies at 4˚C overnight. Blots were then detected with a BeyoECL plus kit (Beyotime Biotechnology).
Real-time polymerase chain reaction. All primer pairs were designed to cross at least one intron. Reverse transcription was performed using Takara Ex Taq (Takara, China) with 50 ng RNA per 20 μl of reaction mixture. For real-time polymerase chain reaction (PCR), we used the ABI PRISM 7900 HT [Applied Biosystems (formerly Applera Corporation), Foster City, CA, USA] in standard mode. In a total 25-μl reaction system, there are 20-μM probes, 20-μM forward/ reverse primers, 12.5-μl ABI TaqMan 2X PCR master mix and 2-μl templates. The experiments were performed three times. PCR products were normalized against the housekeeping gene ß-actin and measurements between samples were compared by cycle threshold (Ct). The primers used in real-time PCR were as follows: forward primers: ABCB1 5'-GCTCAGACAGGATGTGAGTTGGT-3'; ABCC1 5'-AGG TCAAGCTTTCCGTGTACTG-3'; ABCC2 5'-GTGAGGAT TGACACCAACCAGAA-3'; gankyrin 5'-CAATCAAAAT GGCTGTACTCCCTTA-3' reverse primers: ABCB1 5'-CCT GGAACCTATAGCCCCTTTAAC-3'; ABCC1 5'-GGACTT TCGTGTGCTCCTGA-3'; ABCC2 5'-CCCACTTAGGGTA TCTCTATAAATAACCA-3'; gankyrin 5'-TGGTCCTTAG CATCTGGATTAGC-3'.
Results
Evaluation of arsenic-resistant cell line. HepG2/AS was isolated from wild-type HepG2 by a series of stepwise selections via treatment with increasing concentrations of arsenic trioxide from 0.5 to 4 μM, referring to the establishment of arsenic resistant human leukemia cell line K562/AS-3 (11) . We selected the most resistant cell line and named it HepG2/ AS. HepG2/AS was maintained in medium containing 2 μM As 2 O 3 and cultured for 4 weeks before evaluation. The selection and cultivation of SGC7901/AS was the same as for HepG2/AS. HepG2/AS and SGC7901/AS were significantly more resistant to As 2 O 3 than were wild-type cells at concentrations >4 μM, according to the assay of cell growth inhibition performed with the CCK-8 assay (Fig. 1) . HepG2/AS and SGC7901/AS showed cross-resistance to 5-FU (Fig. 1) .
Expression of ABCB1, ABCC1 and ABCC2 in HepG2/AS and SGC7901/AS.
We examined the protein expression of three ABC transporters that had been reported to be highly expressed in other drug-resistant cell lines. Western blot analysis confirmed the different expression of ABCB1, ABCC1, and ABCC2 in HepG2, HepG2/AS, SGC7901 and SGC7901/AS. As shown in Fig. 2 , although four types of cell lines expressed ABCB1 on the membrane, the protein was expressed significantly in two arsenic-resistant cell lines. Similarly, the expression of ABCC2 in HepG2/AS was also increased compared with the wild-type. However, the increase of ABCC2 in SGC7901/AS was slight and the amount of ABCC2 in gastric cancer cells was not as great as that in liver cancer cells. The expression of ABCC1 was increased in HepG2/AS compared with the wild-type. However, there was no obvious expression of ABCC1 detected in either of the gastric cancer cell lines.
To further confirm the expression of three ABCB1, ABCC1 and ABCC2 genes, we used real-time PCR, which showed that the increased expression of ABCB1 gene in HepG2/AS was 2.4-fold that of the wild-type and that the increased expression in SGC7901/AS was ~3.5-fold that of the wild-type (Fig. 3) . The increased expression of the ABCC2 gene in HepG2/AS was ~5.3-fold greater than in the wild-type and the increased expression in SGC7901/AS was ~3.6-fold greater than in the wild-type. The increased expression of the ABCC1 gene in HepG2/AS was ~5-fold greater than in the wild-type, but there was no significantly different expression between SGC7901/ AS and SGC7901. resistant cell lines. However, despite the effective inhibition of ABC transporters by 50 μM verapamil, the survival rate in the resistant group was ~10 to 20% higher than in the wild-type group.
Role of ABC transporters in resistance of

Intracellular regulation of tumor suppressors in HepG2/AS and SGC7901/AS.
We examined the expression of p53 in four cell lines, a key factor in apoptosis induced by arsenic trioxide. As shown in Fig. 2 , the expression of p53 was increased in HepG2/AS and SGC7901/AS, which showed resistance to arsenic cytotoxicity, indicating that the activity of p53 might be inhibited. Next, we examined the expression of two proteins participating in the regulation of p53. We found that the expression of MDM2 was also increased in two resistant cell lines compared with the wild-type. Studies have shown that overexpression of gankyrin suppresses p53-dependent apoptosis in tumor cells. In our study, gankyrin was significantly increased in HepG2/AS but slightly decreased in SGC7901/AS. We again used real-time PCR to analyze the expression of the gankyrin gene in four cell lines. The increased expression of gankyrin in HepG2/AS was ~3.3-fold that of the wild-type. However, the expression of the gankyrin gene in SGC7901/AS was increased by ~2.5-fold over the wild-type, which was a paradoxic finding, considering its protein level. Besides p53, gankyrin can also affect the activity of Rb, another tumor suppressor. Thus, we subsequently examined the expression of Rb and p-Rb (Ser795), which was phosphorylated depending on gankyrin overexpression. The expression of Rb was no different in the resistant cell line vs. the relative wild-type, whereas the expression of p-Rb (Ser795) was increased in two resistant cell lines compared with the wild-type. These results suggested that Rb was inactive and phosphorylated at Ser795 by gankyrin in HepG2/AS; however, the phosphorylation of Rb in SGC7901/AS appeared to have no association with gankyrin.
Discussion
Solid tumors in the digestive tract are common, especially HCC and gastric cancer. Although surgery is the optimal treatment for solid tumors, systemic and partial chemotherapy could be necessary for patients with in situ or metastatic cancer. Decades ago, arsenicals were considered to be carcinogenic toxins. However, after the ability of arsenic trioxide to induce differentiation and apoptosis against APL was discovered, it was extensively used as an effective drug for leukemia. Previously, it has also been used in therapy for solid tumors such as HCC, gastric cancer, colorectal cancer, and renal cancer (18) (19) (20) . Although a significant anti-cancer effect had been reported in preclinical and clinical trials, failure of chemotherapy was reported frequently in patients and some cell lines (5) . Among the reasons anti-cancer drugs fail, the most common is acquired drug resistance.
Although the possible mechanism of arsenic resistance has been investigated in rat liver cells and human leukemia cells, the mechanism of arsenic resistance in human liver and gastric tumors has not been clarified yet. We established two cell lines resistant to arsenic trioxide, HepG2/AS and SGC7901/ AS, derived from human liver cancer cell line HepG2 and human gastric cancer cell line SGC7901, respectively, referring to the establishment of human leukemia cell line K562/AS-3, which is resistant to arsenic trioxide (11) .
Two arsenic-resistant cell lines were cultured in 2 μM As 2 O 3 medium, a concentration that was reportedly clinically achievable without severe side effects (1) and appeared more resistant to arsenic compounds even in 4 μM As 2 O 3 compared with the wild-type. Long-term exposure to low levels of organic arsenicals produced self-tolerance to acute arsenic exposure, accompanied by reduced cellular arsenic accumulation. Studies have also demonstrated increased expression of genes encoding GST isoforms and ABC transporters MRP1, MRP2 and P-gp in cells chronically exposed to arsenic at both the transcriptional and translational levels (13, 21, 22) . GST facilitate the formation of putative arsenic-GSH conjugates, such as arsenic triglutathione and dimethylarsenic diglutathione, resulting in more effective cellular or biliary excretion (23) (24) (25) . Notably, arsenic-GSH conjugates are the substrates of some MRP proteins, which efflux them outside mammalian cells. Therefore, ABC transporters might be the end point in the process of arsenic biotransformation and endue cells with acquired arsenic resistance. Consistently ABCB1, ABCC1 and ABCC2 were significantly increased in HepG2/AS at both the transcriptional and the translational level. In SGC7901/AS, only ABCB1 appeared to have significant expression at both the transcriptional and the translational level. Although there was no significant inhibition of growth in two arsenic-resistant cell lines with 20 μM verapamil, a standard ABCB1 inhibitor (26) , two resistant cell lines partially restored the sensitivity of As 2 O 3 under 50 μM verapamil. The survival in the resistant group was still 10 to 20% higher than that in wild-type group. As verapamil has been considered a chemosensitizer and drug accumulator in multidrug-resistant cells expressing MRPs, arsenic compounds might be the substrates of ABC transporters and were effectively transported outside the membrane by ABCB1, ABCC1, and ABCC2, at least in HepG2/As and SGC7901/AS. 5-FU has been reportedly transported by ABCC5 and ABCC11 only in transfection studies (27, 28) . Although four cell lines were inhibited by 5-FU at a concentration of 100 μg/ml, HepG2/AS and SGC7901/AS appeared more resistant to 5-FU. This suggests that there probably are other mechanisms of arsenic resistance in arsenic-resistant cells.
Apoptosis induced by arsenic trioxide is associated with the induction of reactive oxygen species (ROS) and DNA damage (29) . Then p53 and checkpoint kinases Chk1 and Chk2 are activated, thereby amplifying the DNA damage signal to execute cell cycle checkpoint regulation (30) . It has been reported that apoptosis induced by arsenic trioxide is required for p53 (14, 15) . In our study, p53 levels were increased in two arsenic-resistant cell lines which could be the result of 2 μM As 2 O 3 medium, but the biofunction of p53 would be inhibited by some modulators. Previously, a novel oncoprotein, gankyrin, has been purified and characterized as a component of 19S regulatory subunit of the 26S proteasome (31) , and can bind to MDM2 and facilitates the binding of MDM2 to p53, resulting in ubiquitylation and degradation of p53 (32, 33) . Gankyrin is overexpressed in HepG2/AS at the protein and mRNA level compared with HepG2 but is decreased slightly in SGC7901/AS at the protein level in spite of increasing at the mRNA level. The expression of MDM2 also increased in two arsenic-resistant cell lines. These findings suggest that in HepG2/AS, overexpression of gankyrin and MDM2 contribute to the inhibition of apoptosis induced by p53. In SGC7901/AS, however, gankyrin appears to have a minor part in the suppression of p53. This may be because gankyrin overexpression has been reported mostly in HCCs as playing an oncogenic role of human hepatocarcinogenesis, but no studies have shown an increase of gankyrin in gastric cancer cell lines or pathologic tissues. The blocking of p53-dependent apoptosis may due to the overexpression of MDM2 in SGC7901/AS.
Another tumor suppressor interacting with gankyrin and MDM2 is Rb. Gankyrin competes with p16
INK4A , an inhibitor of cyclin kinases, for binding to cyclin D-dependent kinase 4 (CDK4) (34) . Subsequently, gankyrin conjugates with CDK4 and Rb and makes the phosphorylation of Rb at Ser795. Additionally, MDM2 binds selectively to hypophosphorylated Rb, resulting in Rb degradation via 20S proteasome (35) . In our study, there was no difference in the expression of Rb between two resistant cell lines and relative wild-types, whereas the phosphorylation of Rb at Ser795 increased in two resistant cell lines. It is known that hypophosphorylated Rb represses the transcription of genes controlling the cell cycle through direct protein-protein interactions. Whereas CDK4-mediated phosphorylation of Rb at Ser795 converts Rb to an inactive, phosphorylated state, resulting in the release of E2F transcription factors, activation of DNA synthesis genes and cell cycle progression (36) . Therefore, the arsenic resistance in solid tumor cells may partially be due to the promotion of the cell cycle by the phosphorylated Rb at Ser795, which is induced by the overexpression of gankyrin in HepG2/AS and an unknown pathway in SGC7901/AS.
From our results, we conclude that after diffusion of As 2 O 3 into cytoplasm, it is actively transported outside cellular membrane by ABCB1, ABCC1, or ABCC2 in arsenic-resistant cell lines (Fig. 5) . Although the amount of As 2 O 3 in treated cells is decreased, the retained drugs will induce p53 in nucleus. However, the increased gankyrin and MDM2 in arsenic-resistant cells facilitate the ubiquitination and degradation of p53, thereby abrogating p53-dependent apoptosis. Meanwhile, gankyrin facilitate the phosphorylation of Rb at Ser795 resulting in the releasing of E2F transcription factors and cell cycle progression.
In summary, our findings suggest that chronic use of As 2 O 3 may induce the expression of ABCB1, ABCC1, or ABCC2 in liver and gastric cancer cells, at least in HepG2 and SGC7901. The function of p53 in two arsenic-resistant cell lines incubated with 2 μm As 2 O 3 was inhibited by the overexpression of gankyrin and MDM2 in HepG2/AS and by MDM2 in SGC7901/AS. The phosphorylation of Rb at Ser795 was increased in arsenic-resistant cells, resulting in cell cycle progression, which could be the reason of arsenic resistance. Unfortunately, although four generations of inhibitors toward ABC transporters have been developed, no significant effect has been reported even if the combined therapy is utilized. Reactivation of p53 is another new attractive pharmacological approach for cancer therapy (37, 38) . The combination of As 2 O 3 and small molecule inhibiting MDM2, e.g. Nutlin-3 or MI-219, may have effective anti-tumor activity in resistant and nonresistant liver and gastric cancer cells, which need to be further explored.
